Sun Pharmaceutical Industries' Halol factory has finally had supply restrictions imposed on it by the U.S. Food and Drug Administration lifted, according to the company. Restrictions to certain drugs were made at the particular site after the FDA inspection found quality control failures.
Sun Pharma is now able to continue shipping drugs made at the factory in western India, which had contributed nearly 15 percent to its U.S. revenue in 2015.
The company's Halol facility has the capability to make niche drugs the company is developing. Sun Pharma recently stated its plans to launch three new drugs this year.
Read the Reuters report